Kajalakshmy M. 2022. “Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes”. Journal for ReAttach Therapy and Developmental Diversities 5 (2):788-92. https://doi.org/10.53555/jrtdd.v5i2.3854.